Abbott Abbokinase
Reovirus was found in three lots of in-process urokinase product, FDA reports in a March 16 letter. The reovirus was detected because of testing begun this year by Abbott after FDA found production deficiencies in an inspection last fall ("The Pink Sheet" Feb. 15, p. 9). Finished lots of Abbokinase currently on the market have tested negative for reovirus in Abbott's preliminary test, but FDA noted that the test has not been validated. Additional finished lots of Abbokinase will not be available until further testing and testing validation has been completed
More from Archive
More from Pink Sheet
Two US FDA advisory committees will discuss results from epidemiological studies that attempted to quantify the prevalence, incidence and risk factors for misuse, abuse, overdose and death with opioid analgesics.
Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.
Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry
Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.